Founders Financial Securities LLC Sells 16,726 Shares of Merck & Co., Inc. $MRK

Key Points

• Founders Financial Securities LLC cut its Merck stake by 45.7% in Q4, selling 16,726 shares and leaving it with 19,857 shares valued at about $2.09 million.
• Merck continues to draw support from institutional investors and analysts, with 76.07% of shares held by institutions and several analysts maintaining bullish or overweight ratings.
• The biggest long-term issue remains Keytruda’s eventual loss of exclusivity, but positive pipeline news — including FDA Breakthrough Therapy designation for calderasib with Keytruda — could help support future growth.

Founders Financial Securities LLC reduced its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 45.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,857 shares of the company's stock after selling 16,726 shares during the quarter. Founders Financial Securities LLC's holdings in Merck & Co., Inc. were worth $2,090,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Chesapeake Wealth Management raised its holdings in shares of Merck & Co., Inc. by 0.6% in the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company's stock valued at $1,552,000 after acquiring an additional 87 shares in the last quarter. Syverson Strege & Co raised its holdings in Merck & Co., Inc. by 2.2% in the fourth quarter. Syverson Strege & Co now owns 4,142 shares of the company's stock worth $436,000 after purchasing an additional 90 shares in the last quarter. Westside Investment Management Inc. raised its holdings in Merck & Co., Inc. by 3.1% in the fourth quarter. Westside Investment Management Inc. now owns 3,142 shares of the company's stock worth $331,000 after purchasing an additional 93 shares in the last quarter. Valued Wealth Advisors LLC raised its holdings in Merck & Co., Inc. by 26.9% in the fourth quarter. Valued Wealth Advisors LLC now owns 444 shares of the company's stock worth $47,000 after purchasing an additional 94 shares in the last quarter. Finally, Intrua Financial LLC raised its holdings in Merck & Co., Inc. by 1.1% in the fourth quarter. Intrua Financial LLC now owns 8,604 shares of the company's stock worth $906,000 after purchasing an additional 96 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA granted Breakthrough Therapy designation to calderasib (MK-1084) with Keytruda in a lung cancer indication, a sign the program may move faster and expand Merck’s oncology growth prospects. Article Title
• Positive Sentiment: Analyst coverage and recent articles highlighted Merck’s newer drugs, pipeline assets, and M&A options as potential offsets to looming Keytruda patent expiration, reinforcing the bull case for long-term growth. Article Title
• Positive Sentiment: Merck has also been drawing investor attention as a trending stock and has outperformed the S&P 500 over the past year, suggesting market confidence remains relatively strong. Article Title
• Neutral Sentiment: Merck will participate in the Jefferies Global Healthcare Conference, which could provide an update on strategy but is not itself a major business catalyst. Article Title
• Neutral Sentiment: Shareholders backed board nominees, pay, and auditor ratification at the annual meeting, which reduces governance uncertainty but is unlikely to move the stock much. Article Title
• Negative Sentiment: The main longer-term concern remains Keytruda’s eventual loss of exclusivity, which could pressure Merck’s biggest revenue driver if replacement products do not scale quickly enough. Article Title

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on MRK shares. JPMorgan Chase & Co. boosted their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an "overweight" rating in a report on Monday, April 6th. Zacks Research upgraded shares of Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 17th. Wall Street Zen downgraded shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating in a report on Saturday, May 16th. Barclays started coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They issued an "overweight" rating and a $140.00 target price for the company. Finally, Wells Fargo & Company reduced their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an "overweight" rating for the company in a report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. has an average rating of "Moderate Buy" and a consensus target price of $128.18.

Merck & Co., Inc. Stock Performance

MRK opened at $118.49 on Monday. Merck & Co., Inc. has a 52-week low of $75.40 and a 52-week high of $125.14. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The company has a market cap of $292.66 billion, a P/E ratio of 33.38, a price-to-earnings-growth ratio of 2.67 and a beta of 0.21. The firm's 50-day moving average price is $116.39 and its 200-day moving average price is $111.63.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the prior year, the company posted $2.22 earnings per share. The company's revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 5.16 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.85 per share. The ex-dividend date is Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. Merck & Co., Inc.'s dividend payout ratio is 95.77%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.